Glaxo warns of birth defect from antiepileptic drug

	Tweet

Drugmaker GlaxoSmithKline Plc. warned on Tuesday that there is an increased risk of cleft lip or cleft palate when the company’s antiepileptic drug Lamictal is used during early pregnancy.

The company, following discussions with Health Canada, said cleft palate deformity was detected at “an elevated rate” in infants whose mothers used the treatment during the first three months of pregnancy, compared with those who weren’t exposed to the drug.

Antiepileptic drugs have been associated with oral clefts, while other factors including smoking, heavy alcohol intake, various infections, folic acid deficiency, and vitamin A intoxication, have also contributed. 

Oral clefts occur 0.5 to 2.16 times per 1,000 births.

The company advised patients who are being treated with Lamictal and who are, or intend to become pregnant, to discuss treatment with their doctors. 

RELATED STORIES:
More U.S. doctors facing charges over drug abuse   Counterfeit Internet drugs pose significant risks and discourage vital health checks   Internet tied to rise in drug abuse   Depomed recalls 52 lots of diabetes drug   Preventing avoidable opioid-related deaths top priority for pain medicine field   Concern Over Fast Tracking of New Drugs   US urges doctors to report misleading drug pitches   Novo says Victoza not to blame for 2 Japan deaths   Survey finds 80 pct of U.S. doctors witness mistakes   Vioxx risks can occur within 2 weeks: Canada study   Deaths From Accidental Prescription Drug Overdose on Rise in New Mexico   Merck sought to reformulate Vioxx in 2000

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]